CTI BioPharma Corp. (NASDAQ:CTIC)

CAPS Rating: 1 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.


Player Avatar Allstar13913 (99.84) Submitted: 4/27/2013 10:11:59 PM : Underperform Start Price: $1.18 CTIC Score: -75.61

Worthless Biopharm company. Has a drug twice rejected by the FDA but was approved for European use. AVOID.

Featured Broker Partners